Affordable Access

Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma

Respiratory Medicine
Publication Date
DOI: 10.1016/j.rmed.2006.11.020
  • Asthma
  • Beclometasone Diproprionate
  • Children
  • Hfa 134A
  • Extrafine Aerosol
  • Administration Inhalation
  • Medicine


Summary Beclometasone dipropionate (BDP) extrafine is a hydrofluoroalkane-based, chlorofluorocarbon (CFC)-free inhalation aerosol. This study was conducted to determine whether BDP extrafine and CFC-fluticasone proprionate (FP) aerosols were equivalent in terms of efficacy and tolerability in children with symptomatic mild-to-moderate asthma. Male and female patients (aged 5–12 yr) with an asthma diagnosis for ⩾3 months, peak expiratory flow (PEF) ⩾60% of predicted normal and suboptimal asthma control were randomised to double-blind treatment with BDP extrafine 200 μg day −1 ( n=139) or CFC-FP 200 μg day −1 ( n=141) for up to 18 weeks. After 6 and 12 weeks, study medication was ‘stepped down’ to 100 and 50 μg day −1, respectively, if patients had achieved good asthma control. Patients with poor asthma control discontinued from the study and those with intermediate control continued in the study but did not undergo a dose reduction. The estimated treatment difference in morning PEF% predicted at 6 weeks was −1.9% (90% CI −4.9, 1.0). There was a trend towards a greater increase in forced vital capacity (% predicted) in the BDP extrafine group (5.3 versus 0.4%; p=0.084). A ‘step-down’ in therapy to 100 μg day −1 was possible in 36% and 42% of patients in the BDP extrafine and CFC-FP groups, respectively, at 6 weeks. Both drugs were well tolerated. BDP extrafine and CFC-FP aerosols were equally effective at improving asthma control in children with mild-to-moderate asthma at the same daily dose.

There are no comments yet on this publication. Be the first to share your thoughts.